The need for an iterative process for assessing economic outcomes associated with SSRIs

PharmacoEconomics

Volumn 18, Issue 3, 2000, Pages 205-214

  Skaer, T L ^a,b,c   Sclar, D A ^a,c,d   Robison, L M ^a   Galin, R S ^a,b,e  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Pullman Memorial Hospital   (United States)

^c WASHINGTON STATE UNIVERSITY   (United States)

^d Washington Institute for Mental Illness Research and Training   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; FLUOXETINE; NORTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DEPRESSION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY;

EID: 0033864440     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200018030-00001     Document Type: Article

References (154)

1. Global mortality, diability, and the contribution of risk factors: Global Burden of Disease Study
2. Depression, disability days, and days lost from work in a prospective epidemiologic survey
3. The economic impact of depression in a workplace
4. Depression in the medically ill: Management considerations
5. The added costs of depression to medical care
6. The clinical and financial burden of mood disorders. Cost and outcome
7. The changing rate of major depression Cross-national comparisons
8. Health economic evaluations of antidepressants: A review
9. What does treatment of depression really cost?
10. Service utilization and social morbidity associated with depressive symptoms in the community
11. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey
12. The prevalence and distribution of major depression in a national community sample: The National Comorbidity Survey
13. The economic burden of depression in 1990
14. Trends in the prescribing of antidepressant pharmacotherapy: Office-based visits 1990-1995
15. Epidemiology of depression
16. Recent progress in the epidemiology of major depression
17. Depression in primary care: Review of AHCPR guidelines
18. Depression: A long-term illness
19. Lifetime risk of depression
20. The undertreatment of depression
21. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression
22. Depression. Underrecognition and undertreatment by psychiatrists and other health care professionals
23. The NIMH Depression Awareness, Recognition, and Treatment Program: Structure, aims, and scientific basis
24. Current issues in the treatment of major depression
25. Diagnosing major depression in the elderly: Evidence for response bias in standardized diagnostic interviews?
26. Contemporary management of depression
27. Evolutionary trends in the pharmacotherapeutic management of depression
28. Fluoxetine: A five year review
29. Fluoxetine tenth anniversary update: The progress continues
30. Pharmacokinetics of the newer antidepressants: Clinical relevance
31. Changing patterns of antidepressant use and costs in a health maintenance organization
32. Health care reform-past and future
33. Must we choose between quality and cost containment?
34. Reducing health care costs by reducing the need and demand for medical services. The Health Project Consortium
35. Comparing health care systems: What nations can learn from one another
36. Health care financing: A comparative analysis
37. Issues in mandatory assessment of pharmaceuticals
38. Methodological and conduct principles for pharmacoeconomic research
39. Guidelines for economic analysis of pharmaceutical products: Draft document for Ontario and Canada
40. Cost-effectiveness guidelines for reimbursement of pharmaceuticals: Is economic evaluation ready for its enhanced status?
41. Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry
42. The ecology of medical care
43. Pharmacoeconomics: Integrating economic evaluation into clinical trails
44. Harvesting knowledge from improvement
45. Double-blind randomized comparative study of sertraline and fluoxetine in a depressive outpatient: Medicoeconomic aspects
46. Comparative tolerability profiles of the newer versus older antidepressants
47. Are SSRIs a cost-effective alternative to tricyclics?
48. Efficacy of newer medications for treating depression in primary care patients
49. Selective serotonin reuptake inhibitors: Meta-analysis of efficacy and acceptability
50. Selective serotonin reuptake inhibitors: Meta-analysis of discontinuation rates
51. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: A meta analysis
52. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: A meta analysis
53. Which antidepressant? A commentary from general practice on evidence-based medicine and health economics
54. Are the SSRIs really better tolerated than the TCAs for treatment of major depression?
55. New or old antidepressants? Benefits of new drugs are exaggerated
56. New or old antidepressants? New is better
57. Making cost assessments based on RCTs more useful to decision-makers
58. The relevance of searching for effects under a clinical-trial lamppost: A key issue
59. Economic analysis of treating depression with nefazodone v. imipramine
60. A model to evaluate the cost-effectieness of oral therapies in the management of patients with major depressive disorders
61. Pharmacoeconomic analysis of venlafaxine in the treatment of major depression disorden
62. Comparison of a decision analytic model with results from a naturalistic economic clinical trial: An application to evaluating alternative antidepressants
63. Direct costs of depression: Analysis of treatment costs of paroxetine vs. imipramine in Canada
64. Cost-effectiveness of antidepressant treatment reassessed
65. Can decision analysis adequately represent clinical problems?
66. Modelling cost-effectiveness issues in the treatment of clinical depression
67. A critical review of health-related economic evaluations in Australia: Implications for health policy
68. Antidepressant medication: Dollars and sense
69. Cost-utility in practice: A policy maker's guide to the state of the art
70. The financial implications of starting treatment with a selective serotonin reuptake inhibitor or tricyclic antidepressant in drug-naive depressed patients
71. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment
72. The cost of treatment drop-out in depression A cost-benefit analysis of fluoxetine vs. tricyclics
73. Impact of fluoxetine on work loss in depression
74. Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide
75. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings
76. The role of insurance claims databases in drug therapy outcomes research
77. A comparison of prescribing patterns of selective serotonin reuptake inhibitors in the treatment of depression in primary care in the United Kingdom
78. The treatment of depression: Prescribing patterns of antidepressants in primary care in the UK
79. Cross sectional database analysis of antidepressant prescribing in general practice in the United Kingdom, 1993-5
80. Channeling the three newly introduced antidepressants to patients not responding satisfactorily to previous treatment
81. Course of antidepressant treatment with tricyclic versus selective serotonin reuptake inhibitor agents: A comparison in managed care and fee-for-service environments
82. Changing patterns of antidepressant use and costs in an HMO
83. Prescribing patterns of antidepressant medications for depression in a HMO
84. Trends in the prescription of antidepressants by office-based psychiatrists
85. Changes in the pattern of antidepressant use upon the introduction of the new antidepressants: A prescription database study
86. Minimum effective dose for antidepressants - An obligatory requirement for antidepressant drug evaluation?
87. Outpatient utilization of antidepressants: A prescription database analysis
88. Adequacy and duration of antidepressant treatment in primary care
89. The role of the primary care physician in patients' adherence to antidepressant therapy
90. Augmentation strategies in patients with refractory depression
91. Practice guideline for major depressive disorder in adults
92. Antidepressant pharmacotherapy: Economic outcomes in a health maintenance organization
93. Antidepressant pharmacotherapy: Economic valuation of fluoxetine, paroxetine, and sertraline in a health maintenance organization
94. Evidence-based algorithm for antidepressant pharmacotherapy
95. Economic valuation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression
96. Antidepressant pharmacotherapy: Effect on women's resource utilization within a health maintenance organization
97. Economic outcomes with antidepressant pharmacotherapy: A retrospective intent-to-treat analysis
98. The cost of antidepressant drug therapy failure: A study of antidepressant use patterns in a Medicaid population
99. Patterns of antidepressant use and their relation to costs of care
100. Economic appraisal of citalopram in the management of single-episode depression
101. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: A multivariate analysis
102. Effect of antidepressant therapy on health care utilization and costs in primary care
103. The application of sample selection models to outcomes research: The case of evaluating the effects of antidepressant therapy on resource utilization
104. Economic consequences of selective serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P-450 system
105. Randomized database studies: A new method to assess drugs' effectiveness?
106. Predictors of a medical-offset effect among patients receiving antidepressant therapy
107. A review of methodologies for assessing drug effectiveness and a new proposal: Randomized database studies
108. SSRI antidepressant drug use patterns in the naturalistic setting: A multivariate analysis
109. A framework for drug utilization evaluation in depression: Insights from outcomes research
110. Use of claims data for research on treatment and outcomes of depression care
111. Antidepressant selection and use and healthcare expenditures. An empirical approach
112. Gaps in antidepressant prescribing in primary care in the United Kingdom
113. Antidepressant use in the psychiatrist setting in Austria: A comparison of citalopram, fluoxetine, and paroxetine
114. A naturalistic prospective study of the use of fluoxetine in general psychiatric outpatients
115. Cost-effectiveness comparisons using 'real world' randomized trials: The case of new antidepressant drugs
116. Initial antidepressant choice in primary care: Effectiveness and cost of fluoxetine vs tricyclic antidepressants
117. Depression in Parkinson's disease: A national survey of office-based visits 1990-1995
118. Depression in diabetes mellitus: A national survey of office-based encounters 1990-1995
119. Constraints on antidepressant prescribing and principles of cost-effective antidepressant use
120. Course of antidepressant treatment, drug type, and prescriber's specialty
121. A study of the relationship between patients' attitudes and doctors' prescribing
122. Uncomfortable prescribing decisions: A critical incident study
123. Decision making and prescribing patterns - A literature review
124. Factors which influence the decision whether or not to prescribe: The dilemma facing general practitioners
125. The influence of patients' hopes of receiving a prescription on doctors' perceptions and the decision to proscribe: A questionnaire survey
126. Are patients more satisfied when they receive a prescription? The effect of patient expectations in general practice
127. Prescribing behavior in clinical practice: Patients' expectations and doctors' perceptions of patients' expectations - A questionnaire study
128. Influence of patients' expectations on antibiotic management of acute lower respiratory tract illness in general practice: Questionnaire study
129. Contemporary use of antibiotics in 1089 adults presenting with acute lower respiratory tract illness in general practice in the U.K.: Implications for developing management guidelines
130. Patients' demands for prescriptions in primary care
131. Patient demand for prescriptions: A view from the other side
132. Prescribing and referral in general practice: A study of patients' expectations and doctors' actions
133. Primary care physicians' medical decision making for late-life depression
134. Gender and psychotropic drug use
135. Gender differences in depression in primary care
136. Antidepressant prescribing patterns: A comparison of blacks and whites in a Medicaid population
137. Pressure to prescribe
138. Caring for depression in America: Lessons learned from early findings of the medical outcomes study
139. What factors influence the prescribing of antidepressant pharmacotherapy? An assessment of national office-based encounters
140. Ethnicity and the prescribing of antidepressant pharmacotherapy: 1992-1995
141. Racial variation in antidepressant treatment in a Medicaid population
142. Outcomes of recognized and unrecognized depression in an international primary care study
143. Is depression under-recognised and undertreated?
144. In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in health care
145. Is there a need for standardization of methods in economic evaluations of medicine?
146. Applying pharmacoeconomic and quality-of-life measures to the formulary management process
147. Expanding Medicaid drug formulary coverage. Effects on utilization of related services
148. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies
149. Drug formularies: Myths-in-formation
150. Randomized controlled trials and naturalistic data: Time for a change?
151. Economic comparisons of the pharmacotherapy of depression: An overview
152. Choosing an antidepressant: Effectiveness based pharmacoeconomics